Repligen Co. (NASDAQ:RGEN) Stake Increased by Fred Alger Management LLC

Fred Alger Management LLC grew its holdings in Repligen Co. (NASDAQ:RGEN) by 29.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 398,554 shares of the biotechnology company’s stock after purchasing an additional 90,831 shares during the period. Fred Alger Management LLC owned approximately 0.71% of Repligen worth $59,313,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Toronto Dominion Bank increased its stake in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after buying an additional 89 shares during the last quarter. Ballentine Partners LLC increased its position in Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after buying an additional 105 shares during the last quarter. Diversified Trust Co increased its position in Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after buying an additional 106 shares during the last quarter. Finally, CWM LLC increased its position in Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after buying an additional 114 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on RGEN. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

NASDAQ RGEN opened at $149.99 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a 50-day simple moving average of $140.83 and a 200 day simple moving average of $142.94. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter last year, the company earned $0.23 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. As a group, research analysts forecast that Repligen Co. will post 1.52 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.